Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Centanafadine - Otsuka Pharmaceutical

Next Previous
Drug Profile

Centanafadine - Otsuka Pharmaceutical

Alternative Names: Centanafadine SR; Centanafadine XR; CTN SR; EB-1020; EB-1020 SR

Latest Information Update: 05 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Euthymics Bioscience; Otsuka Pharmaceutical
  • Class Analgesics; Antidepressants; Azabicyclo compounds; Behavioural disorder therapies; Cyclohexanes; Naphthalenes; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder
  • Phase II Major depressive disorder; Smoking withdrawal
  • Discontinued Binge-eating disorder; Neuropathic pain

Most Recent Events

  • 01 Aug 2025 Phase-III clinical trials in Attention-deficit hyperactivity disorder (In adolescents, In children) in Japan (PO) (NCT07087327)
  • 25 Jul 2025 Phase-II/III clinical trials in Attention-deficit hyperactivity disorder (In adolescents, In children) in Japan (PO) (NCT07086313)
  • 16 May 2025 Otsuka Pharmaceutical Development & Commercialization completes the phase II JUNIPER trial in Major depressive disorder (Treatment experienced, Adjunctive therapy) in USA (PO, Capsule, Controlled release) (NCT05536414)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top